Schizophrenia is a severe mental disorder which leads to functional deterioration. Early
detection and intervention are vital for better prognosis. However, the diagnosis of …

Treatments for negative symptoms and cognitive dysfunction in schizophrenia remain issues
that psychiatrists around the world are trying to solve. Their mechanisms may be associated …

Glutamatergic neurotransmission, particularly through the N-methyl-d-aspartate (NMDA)
receptor, has drawn attention for its role in the pathophysiology of schizophrenia. This paper …

Evidence from clinical, preclinical, and post-mortem studies supports the
inflammatory/immune hypothesis of schizophrenia pathogenesis. Less evident is the link …

At present, the diagnosis of schizophrenia is based entirely on phenotype with no
established biologically based examinations for either overall diagnosis or …

Aberrant function of glutamatergic pathways is likely to underlie the pathology of
schizophrenia. Evidence of oxidative stress in the disease pathology has also been …

Hypofunction of N-methyl-D-aspartate glutamate receptors (NMDARs), whether caused by
endogenous factors like auto-antibodies or mutations, or by pharmacological or genetic …

Schizophrenia is a chronic and severe psychiatric disorder that has profound impact on an
individual's life and on society. Thus, developing more effective therapeutic interventions is …

Early response to antipsychotic medications is one of the most important determinants of
later symptomatic and functional outcomes in psychosis. Glutathione and glutamate have …

On the face of it, the treatment of schizophrenia offers lots of choice: there are more than 30
antipsychotic drugs licensed for first-line treatment. However, as they all essentially use the …